Results 201 to 210 of about 38,617 (240)

Multienzyme mevalonate pathway bioreactor

Biotechnology and Bioengineering, 2004
AbstractThe five‐carbon metabolic intermediate isopentenyl diphosphate constitutes the basic building block for the biosynthesis of all isoprenoids in all forms of life. Two distinct pathways lead from amphibolic intermediates to isopentenyl diphosphate.
Autumn, Sutherlin, Victor W, Rodwell
openaire   +2 more sources

Mevalonate Pathway and Human Cancers

Current Molecular Pharmacology, 2017
Mevalonate (MVA) is synthesized from 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) by HMG-CoA reductase (HMG-CoAR). MVA is further metabolized to farnesyl pyrophosphate (FPP), a precursor of cholesterol and sterols. FPP is also converted to geranylgeranyl pyrophosphate, and these lipids are used for post-translational modification of proteins that ...
Seyedeh Zahra, Bathaie, Mahboobeh, Ashrafi, Mahshid, Azizian, Fuyuhiko, Tamanoi   +3 more
openaire   +2 more sources

The mevalonate pathway in breast cancer biology

Cancer Letters, 2022
Breast cancer affects one in eight women during their lifetime. Although diagnostic and therapeutic options have improved, recurrence, metastasis, and therapeutic resistance remain clinical challenges, which affect life quality and prognosis. The mevalonate pathway is an essential part of cellular homeostasis by providing a number of essential ...
Andy, Göbel, Romy M, Riffel, Lorenz C, Hofbauer, Tilman D, Rachner   +3 more
openaire   +2 more sources

Mevalonate Kinase Deficiency: Disclosing the Role of Mevalonate Pathway Modulation in Inflammation

Current Pharmaceutical Design, 2012
Inflammation is a highly regulated process involved both in the response to pathogens as well as in tissue homeostasis. In recent years, a complex network of proteins in charge of inflammation control has been revealed by the study of hereditary periodic fever syndromes.
A. Marcuzzi, S. Crovella, L. Monasta, L. V. Brumatti, M. Gattorno, J. Frenkel   +5 more
openaire   +3 more sources

Biochemistry of the non-mevalonate isoprenoid pathway

Cellular and Molecular Life Sciences, 2011
The non-mevalonate pathway of isoprenoid (terpenoid) biosynthesis is essential in many eubacteria including the major human pathogen, Mycobacterium tuberculosis, in apicomplexan protozoa including the Plasmodium spp. causing malaria, and in the plastids of plants.
Tobias, Gräwert, Michael, Groll, Felix, Rohdich, Adelbert, Bacher, Wolfgang, Eisenreich   +4 more
openaire   +2 more sources

Targeting the Mevalonate Pathway for Treating Esophageal Cancer

Journal of Gastrointestinal Cancer, 2021
To asseess whether the mevalonate pathway can be targeted in managing patients with esophageal cancer.This a narrative review of peer-revieweed publications indexed in MedLine PubMed. The search was conducted by using "Esophageal cancer", "Mevalonate pahtway", "Statins", and "Translational research."The mevalonate pathway is an important metabolic ...
Jonathan V S, Wong, Ali, Fatehi Hassanabad   +1 more
openaire   +2 more sources

Targeting mutant p53 through the mevalonate pathway

Nature Cell Biology, 2016
It is well established that mutant forms of the p53 tumour suppressor acquire pro-oncogenic activities. Inhibition of the mevalonate pathway is now shown to promote degradation of select oncogenic mutant p53 proteins, indicating that destabilization of mutant p53 could be a promising therapeutic strategy.
William, Freed-Pastor, Carol, Prives
openaire   +2 more sources

Basic and Clinical Observations of Mevalonate Depletion on the Mevalonate Signaling Pathway

Current Molecular Pharmacology, 2017
Inhibition of hydroxymethylglutaryl-coenzyme A (HMG-CoA) reductase by pharmaceuticals, commonly referred to as statins, has proven to be an effective and efficient way in reducing cholesterol levels in patients. As a result of this intervention, mevalonate production, formed during cholesterol synthesis, is inhibited.
Alison L, Muller, Darren H, Freed
openaire   +2 more sources

Role of the Mevalonate Pathway in Adrenocortical Tumorigenesis

Hormone and Metabolic Research, 2020
Abstract3-Hydroxy-3-methylglutaryl coenzyme A reductase (HMGCR) is the rate-limiting enzyme of the mevalonate pathway, which generates cholesterol and non-sterol compounds such as isoprenoid, which are involved in key steps of tumorigenesis such as cell growth and proliferation.
Helena Panteliou, Lima-Valassi, Antonio Marcondes, Lerario, Luciana Ribeiro, Montenegro, Maria Candida Barisson Villares, Fragoso, Madson Queiroz, Almeida, Berenice Bilharinho, Mendonca, Chin Jia, Lin   +6 more
openaire   +2 more sources

Anti-Cancer Therapy: Targeting the Mevalonate Pathway

Current Cancer Drug Targets, 2006
The mevalonate pathway has become an important target for anti-cancer therapy. Manipulation of this pathway results in alteration of malignant cell growth and survival in cell culture and animal models, with promising potential for application in human cancers. Mevalonate is synthesized from 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA).
Kelly M, Swanson, Raymond J, Hohl
openaire   +2 more sources